European Journal of Haematology

Papers
(The median citation count of European Journal of Haematology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-06-01 to 2024-06-01.)
ArticleCitations
Changing patterns in the epidemiology of β‐thalassemia137
COVID‐19 vaccine‐associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome102
COVID‐19 coagulopathy: An in‐depth analysis of the coagulation system92
The hematologic consequences of obesity73
Haematological manifestations of COVID‐19: From cytopenia to coagulopathy71
Clinical course and risk factors for mortality from COVID‐19 in patients with haematological malignancies69
Association of anticoagulation dose and survival in hospitalized COVID‐19 patients: A retrospective propensity score‐weighted analysis63
Blinatumomab in pediatric patients with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia38
Pairing MCL‐1 inhibition with venetoclax improves therapeutic efficiency of BH3‐mimetics in AML37
Prevalence of pyruvate kinase deficiency: A systematic literature review36
The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies36
Real‐world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib34
Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus32
Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series30
Anticoagulation strategies in extracorporeal circulatory devices in adult populations28
The incidence, complications, and treatment of iron deficiency in pregnancy27
Patient outcomes in light chain (AL) amyloidosis: The clock is ticking from symptoms to diagnosis27
Quality of life in patients of chronic lymphocytic leukemia using the EORTC QLQ‐C30 and QLQ‐CLL17 questionnaire26
CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real‐world practice26
COVID‐19 and thalassaemia: A position statement of the Thalassaemia International Federation26
One‐year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab25
Review of Vitamin B12 deficiency in pregnancy: a diagnosis not to miss as veganism and vegetarianism become more prevalent23
Primary pancreatic lymphoma: Clinical presentation, diagnosis, treatment, and outcome23
Current understanding and future implications of sepsis‐induced thrombocytopenia23
SARS‐CoV‐2 infection among patients with haematological disorders: Severity and one‐month outcome in 66 Danish patients in a nationwide cohort study22
The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: A retrospective analysis of the UK’s population‐based haematological malignancy re22
Regional outcomes of severe acute respiratory syndrome coronavirus 2 infection in hospitalised patients with haematological malignancy22
Prognostic impact and risk factors of cancer‐associated thrombosis events in stage‐IV cancer patients treated with immune checkpoint inhibitors22
Fecal microbiota transfer for refractory intestinal graft‐versus‐host disease — Experience from two German tertiary centers22
The role of ROTEM variables based on clot elasticity and platelet component in predicting bleeding risk in thrombocytopenic critically ill neonates22
Long‐term follow‐up of patients with venous thromboembolism and COVID‐19: Analysis of risk factors for death and major bleeding21
Long‐term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2‐year results from two pivotal phase 3 studies21
Monitoring treatment response and disease progression in myeloma with circulating cell‐free DNA21
Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti‐tumor activity in multiple myeloma20
Clinical prevalence and outcome of cardiovascular events in the first 100 days postallogeneic hematopoietic stem cell transplant19
Effectiveness and safety of apixaban and rivaroxaban for acute venous thromboembolism therapy in patients with extremes in bodyweight19
Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 201919
Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)19
Comorbidities in multiple myeloma and implications on survival: A population‐based study18
Reasons and consequences of COVID‐19 vaccine failure in patients with chronic lymphocytic leukemia18
Favorable COVID‐19 course despite significant comorbidities in a ruxolitinib‐treated patient with primary myelofibrosis18
Characteristics of peripheral blood differential counts in hospitalized patients with COVID‐1918
Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression18
Comorbidities and complications in adults with pyruvate kinase deficiency18
Sickle cell trait and the potential risk of severe coronavirus disease 2019—A mini‐review17
Clinical predictors of SARS‐CoV‐2 neutralizing antibody titers in COVID‐19 convalescents: Implications for convalescent plasma donor recruitment16
Outcome of COVID‐19 in multiple myeloma patients in relation to treatment16
The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: A systematic review and meta‐analysis16
Emicizumab treatment: Impact on coagulation tests and biological monitoring of haemostasis according to clinical situations (BIMHO group proposals)16
Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement15
Validation of the HScore and the HLH‐2004 diagnostic criteria for the diagnosis of hemophagocytic lymphohistiocytosis in a multicenter cohort15
Iron chelation therapy15
T cell–mediated autoimmunity in immune thrombocytopenia14
Daratumumab for relapsed AL amyloidosis—When cumulative real‐world data precedes clinical trials: A multisite study and systematic literature review14
Organ sparing total marrow irradiation compared to total body irradiation prior to allogeneic stem cell transplantation14
Acquired aplastic anemia following SARS‐CoV‐2 vaccination13
Janus‐faced course of COVID‐19 infection in patients with hematological malignancies13
Impact of body mass index on relapse in children with acute lymphoblastic leukemia treated according to Nordic treatment protocols13
Bone lesions in hairy cell leukemia: Diagnosis and treatment13
Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols13
Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma in the real world13
The role of oral iron in the treatment of adults with iron deficiency13
Safety of apixaban compared to warfarin in hemodialysis patients: Do antiplatelets make a difference?12
Impact of a comprehensive geriatric assessment on decision‐making in older patients with hematological malignancies12
The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study12
Role of pre‐transplant MRD level detected by flow cytometry in recipients of allogeneic stem cell transplantation with AML12
Real‐world data on voxelotor to treat patients with sickle cell disease12
Assessing the risk of thromboembolism in cancer patients receiving immunotherapy12
White blood count, D‐dimers, and ferritin levels as predictive factors of pulmonary embolism suspected upon admission in noncritically ill COVID‐19 patients: The French multicenter CLOTVID retrospecti12
The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient‐reported insights on symptoms and qual12
Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic‐phase CML in clinical practice: 3‐year European SIMPLICITY data12
Early report on the severity of COVID‐19 in hematologic patients infected with the SARS‐CoV2 omicron variant12
Letter to the Editor: Fine‐needle aspiration cytology and core‐needle biopsy in the diagnosis of lymphadenopathies: Words of endorsement12
The efficacy and safety of DOACs versus LMWH for cancer‐associated thrombosis: A systematic review and meta‐analysis11
A 3′ tRNA‐derived fragment produced by tRNALeuAAG and tRNALeuTAG is associated with poor prognosis in B‐cell chronic lymphocytic leukemia, independently of classical prognostic f11
Recombinant factor VIII Fc for the treatment of haemophilia A11
Next‐generation sequencing in hypoplastic bone marrow failure: What difference does it make?11
Lymph node core needle biopsy for the diagnosis of lymphoproliferative disorders: A word of caution11
Cellular and humoral response to the fourth BNT162b2 mRNA COVID‐19 vaccine dose in patients with CLL11
Long‐term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome–positive leukemia resistant or intolerant to prior therapy10
Principles of care for acquired hemophilia10
Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysis10
Clinical efficacy of mogamulizumab for relapsed/refractory aggressive adult T‐cell leukemia/lymphoma: A retrospective analysis10
Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1‐mRNA expression in patients with AML and MDS10
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group10
VEXAS syndrome: A review of bone marrow aspirate and biopsies reporting myeloid and erythroid precursor vacuolation10
Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries10
Real‐world treatment patterns and outcomes in non‐transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom10
Lymph node core biopsies reliably permit diagnosis of lymphoproliferative diseases. Real‐World Experience from 554 sequential core biopsies from a single centre10
Haploidentical transplantation in pediatric non‐malignant diseases: A retrospective analysis on behalf of the Spanish Group for Hematopoietic Transplantation (GETH)10
Combination of brentuximab‐vedotin and ifosfamide, carboplatin, etoposide in relapsed/refractory peripheral T‐cell lymphoma10
The value of screening biopsies in light‐chain (AL) and transthyretin (ATTR) amyloidosis10
Immune thrombocytopenic purpura secondary to COVID‐19 vaccination: A systematic review10
High levels of immunoglobulin expression predict shorter overall survival in patients with acute myeloid leukemia9
CAR‐T cell therapy for patients with hematological malignancies. A systematic review9
Characteristics and recognition of early infections in patients treated with commercial anti‐CD19 CAR‐T cells9
Progressive multifocal leukoencephalopathy in the context of newer therapies in hematology and review of new treatment strategies9
The hemostatic and thrombotic complications of liver disease9
Doubtful precipitation of hemolysis by hydroxychloroquine in glucose‐6‐phosphate dehydrogenase‐deficient patient with COVID‐19 infection9
Anti‐thymocyte globulin and post‐transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts9
Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia9
Molecular pharmacology in complement‐mediated hemolytic disorders9
Refractory autoimmune cytopenias in pediatric Evans syndrome with underlying systemic immune dysregulation9
MALT‐1 as a novel therapeutic target for adult T‐cell leukemia9
Image‐guided core needle biopsy as the first‐line diagnostic approach in lymphoproliferative disorders—A review of the current literature9
Treatment horizon in multiple myeloma8
Late occurrence of progressive multifocal leukoencephalopathy after anti‐CD19 chimeric antigen receptor T‐cell therapy8
Pain and functional disability amongst adults with moderate and severe haemophilia from the Irish personalised approach to the treatment of haemophilia (iPATH) study8
Thromboembolic complications in autoimmune hemolytic anemia: Retrospective study8
POEMS syndrome: A multisystem clonal disorder8
Lymphoid malignancy in common variable immunodeficiency in a single‐center cohort8
Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma8
Clonal cytopenia of undetermined significance (CCUS) with dysplasia is enriched for MDS‐type molecular findings compared to CCUS without dysplasia8
Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: A systematic literature review and meta‐analysis8
Clinical benefit of ixazomib plus lenalidomide‐dexamethasone in myeloma patients with non‐canonical NF‐κB pathway activation8
Matched sibling donor stem cell transplantation for sickle cell disease: Results from the Spanish group for bone marrow transplantation in children8
Management of rare inherited bleeding disorders: Proposals of the French Reference Centre on Haemophilia and Rare Coagulation Disorders8
Application of comprehensive geriatric assessment in predicting early mortality among elder patients with B‐cell lymphoma receiving immunochemotherapy8
Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the “Ph1‐negative Myeloproliferative Neoplasms Latium Group”8
Adverse prognostic impact of regulatory T‐cells in testicular diffuse large B‐cell lymphoma8
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents7
Survival in autoimmune hemolytic anemia remains poor, results from a nationwide cohort with 37 years of follow‐up7
Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance7
Clonal haematopoiesis of indeterminate potential and impaired kidney function—A Danish general population study with 11 years follow‐up7
Survival trends in elderly myeloma patients7
Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco‐economic assessment7
Data‐driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary7
Neutralizing antibody responses against SARS‐CoV‐2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination7
mRNA COVID‐19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta‐analysis7
Impact of platelets on major thrombosis in patients with a normal white blood cell count in essential thrombocythemia7
Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple‐class relapsed/refractory multiple myeloma (RRMM)7
Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax‐based salvage therapies7
COVID‐19 complicated by parainfluenza co‐infection in a patient with chronic lymphocytic leukemia7
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics7
Pre‐transplant minimal residual disease assessment and transplant‐related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation7
The role of CUDC‐907, a dual phosphoinositide‐3 kinase and histone deacetylase inhibitor, in inhibiting proliferation of adult T‐cell leukemia7
Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?7
Intracranial hemorrhage in newly diagnosed non‐promyelocytic acute myeloid leukemia patients admitted for intensive induction chemotherapy7
Characteristics and potential biomarkers of adult sickle cell patients with chronic pain6
A retrospective study of treosulfan versus busulfan‐based conditioning in pediatric patients6
Direct oral anticoagulants versus warfarin in patients with single antibody‐positive anti‐phospholipid syndrome6
Soluble programmed cell death protein 1 (sPD‐1) and the soluble programmed cell death ligands 1 and 2 (sPD‐L1 and sPD‐L2) in lymphoid malignancies6
Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International Paroxysmal Nocturnal Hemoglobinuria Registry6
Platelet transfusion and tranexamic acid to prevent bleeding in outpatients with a hematological disease: A Dutch nationwide survey6
Prevalence and risk factors for Pulmonary Hypertension associated with chronic Myeloproliferative Neoplasms6
A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre‐ibrutinib era6
The management, outcome, and postpartum disease course of 41 pregnancies in 20 women with polycythemia vera6
Long‐term tolerability of phosphodiesterase‐5 inhibitors in pulmonary hypertension of sickle cell disease6
Translation, validation, and usability of the International Society on Thrombosis and Haemostasis Bleeding Assessment Tool (Self‐ISTH‐BAT)6
Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T‐cell leukemia/lymphoma6
JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO)6
Oxidative stress, inflammation, blood rheology, and microcirculation in adults with sickle cell disease: Effects of hydroxyurea treatment and impact of sickle cell syndrome6
Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia cases6
Bleeding complications in bcrabl‐negative myeloproliferative neoplasms (MPN): A retrospective single‐center study of 829 MPN patients6
Life expectancy and cause of death in individuals with haemophilia A and B in Norway, 1986‐20186
Efficacy of Helicobater pylori eradication in patients with diffuse large B‐cell lymphoma of the stomach: A systematic review6
Integrin expression and adhesivity to fibronectin in primary acute myeloid leukemia cells: Impact of NPM1 and FLT3 mutations6
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients6
Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis6
Use of midostaurin in mixed phenotype acute leukemia with FLT3 mutation: A case series6
“Ex‐vivo” T‐cell depletion in allogeneic hematopoietic stem cell transplantation: New clinical approaches for old challenges6
CAR‐T cell therapy in hematological malignancies: Where are we now and where are we heading for?6
Racial and ethnic differences in sickle cell disease within the United States: From demographics to outcomes6
Post‐transplant maintenance therapy in patients with FLT3‐mutated acute myeloid leukemia: Real‐world treatment patterns and outcomes6
Teclistamab‐cqyv in multiple myeloma5
Immune thrombocytopenia in adults: A single‐centre review of demographics, clinical features and treatment outcomes5
Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non‐interventional study POSEIDON and comparison with the pivotal phase 3 clinical trial5
Predicting primary treatment failure using interim FDG‐PET scanning in diffuse large B‐cell lymphoma5
Systematic review of hematuria and acute renal failure with tranexamic acid5
Circulating endothelial cells and endothelial progenitor cells as potential predictors of acute GVHD after allogeneic hematopoietic stem cell transplantation5
Non‐myeloablative matched sibling stem cell transplantation with the optional reinforced stem cell infusion for patients with hemoglobinopathies5
Validation of the Alternative International Prognostic Score‐E (AIPS‐E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O‐CLL1‐GISL protocol5
Assessment of von Willebrand disease and pregnancy outcomes at regional Australian hospitals5
Incidence and socioeconomic factors in older adults with acute myeloid leukaemia: Real‐world outcomes from a population‐based cohort5
Transfusion requirements in patients with COVID‐195
Clinical utility of targeted next‐generation sequencing panel in routine diagnosis of hereditary hemolytic anemia: A national reference laboratory experience5
Despite warnings, co‐medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH‐depe5
Clinical outcomes following bone marrow transplantation in patients with sickle cell disease: A cohort study of US Medicaid enrollees5
Bone marrow CD3+CD56+ regulatory T lymphocytes (TR3−56 cells) are inversely associated with activation and expansion of bon5
Prevalence of non‐adherence and non‐compliance during maintenance therapy in adults with acute lymphoblastic leukemia and their associations with survival5
Incidence of adult primary immune thrombocytopenia in England—An update5
Desmopressin as a hemostatic and blood sparing agent in bleeding disorders5
Post‐transplantation erythrocytosis in kidney transplant recipients—A retrospective cohort study5
Evaluation of soluble fibrin monomer complex in patients in SARS‐CoV‐2 COVID‐19 infection‐associated coagulopathy5
Baseline serum B‐cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma5
Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease5
Long‐term outcome in patients with follicular lymphoma following high‐dose therapy and autologous stem cell transplantation5
Risk factors for invasive fungal infection in 5‐azacytidine treated patients with acute myeloid leukemia and myelodysplastic syndrome5
Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro‐prospective observational study5
The evolution of immune dysfunction in multiple myeloma5
Outcomes after intensive care unit admission in newly diagnosed diffuse large B‐cell lymphoma patients: A real‐life study5
Perioperative management for patients with von Willebrand disease: Defining the optimal approach5
A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma5
Clinical and microbiological impact of long‐term discontinuation of fluoroquinolone prophylaxis in haematological patients with prolonged profound neutropenia5
Major central nervous system complications after allogeneic stem cell transplantation: A large retrospective study on 888 consecutive adult patients5
Patterns of previous and secondary malignancies in patients with multiple myeloma4
Graft‐versus‐mastocytosis effect after donor lymphocyte infusion: Proof of principle4
Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first‐line treatment of systemic light chain amyloidosis in the UK4
Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: A systematic review4
VEGFR2 and VEGFA polymorphisms are not associated with an inferior prognosis in Caucasian patients with aggressive B‐cell lymphoma4
Congenital erythrocytosis4
Income, education and their impact on treatments and survival in patients with myelodysplastic syndromes4
Radiation‐free myeloablative conditioning consisting of fludarabine added to full‐dose busulfan and cyclophosphamide in single‐unit cord blood transplantation for adults4
Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre‐ibrutinib era: A population‐based study4
Systematic review of survival outcomes for relapsed or refractory adult T‐cell leukemia‐lymphoma4
Retrospective study of treatment patterns and outcomes post‐lenalidomide for multiple myeloma in Canada4
IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients4
A regulatory element in the 3′‐untranslated region of CEBPA is associated with myeloid/NK/T‐cell leukemia4
Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis4
Hematopoietic cell transplantation for Diamond Blackfan anemia: A report from the Pediatric Group of the Brazilian Bone Marrow Transplantation Society4
Herombopag promotes platelet engraftment and decreases platelet transfusion after allogeneic hematopoietic stem cell transplantation4
Pixantrone in patients with relapsed/refractory diffuse large B‐cell lymphoma: A real‐life, retrospective, multicenter trial on behalf of the “RTL” (Regional Tuscan Lymphoma network)4
Luspatercept, a two‐edged sword in beta‐thalassemia‐associated paravertebral extramedullary hematopoietic masses (EHMs)4
Vitamin E and acute graft‐versus‐host disease after myeloablative allogeneic hematopoietic cell transplantation4
Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma: Feasibility of MTX‐based regimens in clinical routine4
Response rates of extra‐nodal diffuse large B cell lymphoma to anti‐CD19‐CAR T cells: A real word retrospective multicenter study4
Characterization and prognostic implication of delayed complete response in AL amyloidosis4
Histology of the spleen in immune thrombocytopenia: clinical‐pathological characterization and prognostic implications4
Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 study4
Comorbidity profile of adult survivors at 20 years following allogeneic hematopoietic cell transplantation4
Long‐term outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in a real‐world setting4
Tyrosine kinase inhibitors and tumor lysis syndrome in hematologic malignancies: A systemic review4
Full or intensity‐reduced high‐dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma4
Anti‐thymocyte Globulin and Post‐Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen‐A and ‐B mismatched donors4
Clinical implications of NUP98::NSD1 fusion at diagnosis in adult FLT3‐ITD positive AML4
Artificial intelligence in the prediction of venous thromboembolism: A systematic review and pooled analysis4
Venetoclax‐based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia4
Antibody titers after SARS‐CoV‐2 mRNA vaccination in patients with aplastic anemia—A single‐center study4
Single UM171‐expanded cord blood transplant can cure severe idiopathic aplastic anemia in absence of suitable donors4
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate‐risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute4
Efficacy of COVID‐19 vaccination in adult patients with sickle cell disease during the Omicron wave in France4
Implementation of International Prognostic Index with flow cytometry immunophenotyping for better risk stratification of chronic lymphocytic leukemia4
Changes in body mass index during treatment of childhood acute lymphoblastic leukemia with the Nordic ALL2008 protocol4
Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis4
Standardization for obtaining blood viscosity: A systematic review4
Immune‐related adverse events in cancer patients being treated with immune checkpoint inhibitors4
Antigen loss following CAR‐T cell therapy: Mechanisms, implications, and potential solutions4
Myocardial strain is associated with adverse cardiac events in patients treated with chimeric antigen receptor (CAR) T‐cell therapy4
Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first‐line systemic treatment or best supportive care: A multicenter inte4
Clinical efficacy of retreatment of daratumumab‐based therapy (D2) in daratumumab‐refractory multiple myeloma4
Non‐driver gene mutation analysis in a large cohort of polycythemia vera and essential thrombocythemia4
The impact of COVID‐19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single‐center experience4
Luspatercept in combination with recombinant erythropoietin in patients with myelodysplastic syndrome with ring sideroblasts: Stimulating early and late‐stage erythropoiesis3
Maintenance therapy in transplant ineligible adults with newly‐diagnosed multiple myeloma: A systematic review and meta‐analysis3
Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: Real‐world findings from the International Paroxysmal Nocturnal He3
Conditioning with melphalan 200 mg/m2 and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care3
Incidence, prognostic factors, and survival outcomes in patients with blastic plasmacytoid dendritic cell neoplasm: A retrospective study in the Surveillance, Epidemiology, and End Results database3
High expression of AP2M1 correlates with worse prognosis by regulating immune microenvironment and drug resistance to R‐CHOP in diffuse large B cell lymphoma3
Pixantrone as a bridge to CAR‐T treatment in high‐grade transformation of follicular lymphoma3
Haematology Outcomes Network in Europe (HONEUR)—A collaborative, interdisciplinary platform to harness the potential of real‐world data in hematology3
0.10961103439331